Galderma Delivers Record Sales of $2.4 Billion in H1 2025

Galderma Group AG, a dermatology category leader, delivered record net sales of $2.448 Billion for the first half of 2025, officials said.

The gain represents net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix. The increase reflects double-digit growth in both international markets and the US, with strong performance across all product categories, including year-on-year growth of 9.8% for injectable aesthetics, 7.7% for dermatological skincare and 26.9% for therapeutic dermatology at constant currency.

“Galderma’s strong performance in the first half of 2025 underscores the impact of our executional excellence across product categories and the continued ramp-up of our two potential blockbuster launches, Nemluvio and Relfydess,” said Galderma CEO Flemming rnskov. “Reflecting this strong progress and confidence in the business, we are raising our full-year guidance on net sales. With the establishment of our new US headquarters in Miami and sustained scientific momentum, we are also sharpening our focus – accelerating growth and moving from category leadership to becoming a true powerhouse in dermatology.”

Significant progress has been made on the launch of innovation, including Nemluvio, which continues to outperform, delivering $131 million in sales, the ongoing positive uptake of Relfydess now launched in 17 markets, and geographic expansion in fillers and biostimulators.

The company experienced growth in core EBITDA, delivering $555 million, up 9.5% year-on-year at constant currency, with a slightly higher than expected core EBITDA margin for the first half of 22.7%.

Raising 2025 full-year guidance on net sales, the company expects growth of 12-14% at constant currency (previously 10-12%) and confirming guidance on core EBITDA margin of approximately 23% at constant currency.